Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New therapies under development promise improved relief for Non-Hodgkin’s Lymphoma cancer patients


Technical Insights’ Genetic Technology Alert

Biotech companies and researchers across the world are focusing on the development of new therapies for the treatment of Non-Hodgkin’s Lymphoma (NHL) cancer, a lethal and malignant disease that is spreading at an alarming rate.

"About 300,000 people in the United States are affected by NHL and it causes about 23,000 deaths each year in the U.S. alone," says Technical Insights Analyst Al Hester. "This has created a greater need for advanced NHL therapies."

Rituxan (rituximab), from the California-based IDEC Pharmaceuticals, was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of a particular form of NHL. It has found widespread market acceptance and its sales surpassed the $1 billion per year mark.

The efficaciousness of the drug challenges developers of new therapies to discover treatment with some distinct advantages to differentiate their products and provide better relief for patients.

"The need for improved lymphoma treatments has by no means disappeared and a large market awaits developers of successful new products," says Hester.

Sensing the potential, many biotech firms have joined the global race for developing new NHL therapies despite being confronted by high production costs.

"Most of the new lymphoma therapies under development are monoclonal antibodies," says Hester. "These antibodies are high-priced proteins and, therefore, they are expensive to manufacture and also inconvenient to administer to the patients."

However, they can be generated to target specific therapeutic molecules. Biotech firms, betting on monoclonals for developing advanced lymphoma therapeutics, are targeting CD20 antigen that may be found on normal, as well as abnormal B cells. In addition, other antigens such as CD4, CD22, and CD30 are being targeted.

Some biotech firms are also trying gene therapy and vaccines to treat patients. These treatment methods could be advantageous as they avoid some of the side effects often associated with monoclonal antibodies, as well as the difficulties in gaining FDA approval.

The studies conducted by Genetic Technology Alert has revealed that the therapies market is capable of generating revenues worth more than $5 billion per year, as there is a steady increase in patient base.

New analysis by Technical Insights, a business unit of Frost & Sullivan (, featured in the Genetic Technology Alert, presents a critical insight of various therapies that are under research and different phases of clinical trials. The research also discusses the different approaches to treatment and highlights the prime qualities of these potential drugs. This is likely to provide a bird’s eye view of the emerging market opportunities.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and reports.

This analysis is part of the Genetic Technology Alert, which includes market insights on new developments in genetic technologies for the industry. Copies of the alert and interviews are available to the press.

Frost & Sullivan, an international growth consultancy, has been supporting clients’ expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies include custom strategic consulting, market intelligence and management training. Our mission is to forge partnerships with our clients’ management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan’s network of consultants, industry experts, corporate trainers and support staff, spans the globe with offices in every major country.

Julia Paulson | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>